BRI launches GentiBio to develop engineered regulatory T cells for autoimmune and inflammatory diseases
BRI has entered into an exclusive licensing agreement with newly formed GentiBio to develop antigen specific engineered regulatory T cells (EngTreg) to restore immune tolerance and treat autoimmunity, alloimmunity, autoinflammatory and allergic diseases. GentiBio's unique technologies overcome many of the current limitations of Tregs therapeutics. More
Your donation to the COVID-19 Rapid Response Fund will directly support urgent research into the immune system response to the virus. With your help, we can get to answers faster to bring an end to this public health crisis.